Literature DB >> 18438924

Huperzine A attenuates mitochondrial dysfunction after middle cerebral artery occlusion in rats.

Chun Yan Zheng1, Hai Yan Zhang, Xi Can Tang.   

Abstract

Mitochondrial dysfunction has been proved to contribute to ischemia-induced brain damage. In this study, which used a rat middle cerebral artery occlusion (MCAO) model, the protective effects of huperzine A (HupA) against mitochondrial dysfunction and brain damage were investigated. MCAO for 45 min followed by 4 hr of reperfusion significantly impaired the activities of mitochondrial respiratory chain enzymes (complex I, complex II-III, and complex IV) and alpha-ketoglutarate dehydrogenase, increased the production of reactive oxygen species (ROS), and induced mitochondrial swelling. Pretreatment of HupA at 0.1 mg/kg significantly preserved respiratory chain enzyme activities, decreased ROS production, and attenuated mitochondrial swelling. It could also significantly attenuate the neurological deficits (after 4 or 24 hr reperfusion) and reduce infarct volumes (after 24 hr reperfusion). Moreover, HupA protected isolated nonsynaptosomal mitochondria from calcium-induced damage in vitro by preserving mitochondrial membrane potential and decreasing ROS production. Overall, the present study indicates that HupA can ameliorate MCAO-induced mitochondrial dysfunction, and this might partially contribute to its protective effect on brain damage after 24 hr of reperfusion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438924     DOI: 10.1002/jnr.21681

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

Review 1.  Herbal medicine in the treatment of Alzheimer's disease.

Authors:  Jian-guo Wu; Yan-yan Wang; Zi-lv Zhang; Bin Yu
Journal:  Chin J Integr Med       Date:  2014-04-22       Impact factor: 1.978

Review 2.  A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Authors:  Mayuri Shukla; Prapimpun Wongchitrat; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2022-02-05       Impact factor: 3.996

Review 3.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

4.  New insights into huperzine A for the treatment of Alzheimer's disease.

Authors:  Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2012-09-03       Impact factor: 6.150

5.  Examining the interactome of huperzine A by magnetic biopanning.

Authors:  Wei Guo; Shupeng Liu; Jinliang Peng; Xiaohui Wei; Ye Sun; Yangsheng Qiu; Guangwei Gao; Peng Wang; Yuhong Xu
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

6.  By improving regional cortical blood flow, attenuating mitochondrial dysfunction and sequential apoptosis galangin acts as a potential neuroprotective agent after acute ischemic stroke.

Authors:  Shaojing Li; Chuanhong Wu; Li Zhu; Jian Gao; Jing Fang; Defeng Li; Meihong Fu; Rixin Liang; Lan Wang; Ming Cheng; Hongjun Yang
Journal:  Molecules       Date:  2012-11-09       Impact factor: 4.411

7.  An effective solution to discover synergistic drugs for anti-cerebral ischemia from traditional Chinese medicinal formulae.

Authors:  Shaojing Li; Chuanhong Wu; Jianxin Chen; Peng Lu; Chang Chen; Meihong Fu; Jing Fang; Jian Gao; Li Zhu; Rixin Liang; Xin Shen; Hongjun Yang
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

Review 8.  One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke.

Authors:  Han-Sen Chen; Su-Hua Qi; Jian-Gang Shen
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 9.  Mitochondrial MPTP: A Novel Target of Ethnomedicine for Stroke Treatment by Apoptosis Inhibition.

Authors:  Yangxin Li; Jiayi Sun; Ruixia Wu; Jinrong Bai; Ya Hou; Yong Zeng; Yi Zhang; Xiaobo Wang; Zhang Wang; Xianli Meng
Journal:  Front Pharmacol       Date:  2020-03-25       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.